2022 China's new coronavirus vaccine production how much

Data disclosed by China's Ministry of Industry and Information Technology (MIIT) shows that the annual production capacity of China's new coronavirus vaccine is more than 7 billion doses, and the output is more than 5.5 billion doses.

He Yaqiong, director of the Department of Consumer Goods Industry of China's Ministry of Industry and Information Technology (MIIT), said at a press conference on the theme of "Promoting the Consumer Goods Industry to Increase Variety, Improve Quality and Create Brands" that in response to the recent outbreaks of the disease in China that have spread to many points and occurred frequently in many places, the MIIT took the first time to communicate with the provinces, autonomous regions, and municipalities that have experienced the outbreaks and strengthened its efforts to improve the quality of the vaccine. The new coronavirus detection reagents, protective gear, therapeutic drugs and vaccines and other key medical supplies production scheduling, close tracking and monitoring of the production and supply of key enterprises.

Till now, the weekly production capacity of key enterprises for antigen detection exceeds 500 million doses, the weekly production capacity of key enterprises for nucleic acid detection exceeds 200 million doses, the weekly production capacity of key enterprises for N95/KN95 masks exceeds 100 million, the weekly production capacity of key enterprises for protective suits exceeds 3 million, the weekly production capacity of Azulfidine exceeds 700,000, and the annual production capacity of vaccines for the new coronavirus exceeds 7 billion doses, and the output exceeds 5.5 billion doses, which can satisfy the current demand for new coronavirus. More than 5.5 billion doses, can meet the current epidemic prevention and control situation.

He Yaqiong said, the next step, the Ministry of Industry and Information Technology will continue to improve the key medical supplies production scheduling and supply security, strengthen the supply and demand for accurate docking, to ensure timely and adequate supply; closely track the progress of the new test reagents, therapeutic drugs and vaccine R & D listed in a timely manner, to guide the enterprise to do a good job of the scale of the production of preparations; to support enterprises to carry out international cooperation, to assist developing countries to enhance the localization of production capacity.